Quintiles acquires Expression Analysis
To boost its genomics services and advance personalised medicine
Quintiles, a US-based clinical research organisation, has acquired Expression Analysis (EA), a provider of genomics testing and analysis to biopharma, academic, government and non-profit customers.
Financial terms were not disclosed.
EA has about 77 employees, most based at its offices near Research Triangle Park in North Carolina.
The firm provides whole genome to focused-set gene expression and genotyping assays, along with next-generation sequencing services, sequence enrichment technologies and bioinformatics support.
Quintiles says this is the latest in a series of acquisitions and partnerships aimed at using the power of genomics to understand diseases better; develop diagnostic tools; and deliver safer, more effective therapies based on the genetic makeup of the disease and the patient.
‘The addition of EA’s Genomic Know-How to Quintiles is another step forward in our efforts to bring personalised medicine into mainstream drug development,’ said Thomas Wollman, senior vp of Quintiles Global Laboratories. ‘Its expertise in genetic sequencing and advanced bioinformatics is essential to understanding diseases and drugs at the molecular level. That’s a huge step in creating more value across the healthcare spectrum.’
Quintiles Global Laboratories supports trials worldwide with wholly owned facilities in the US, Europe, South Africa, India, China, Singapore and Japan, and a tightly coordinated network of affiliate laboratories in Argentina and Brazil.